In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

"Real zero" fluoroscopy AVNRT ablation

Session Poster session 1

Speaker Franco Zoppo

Congress : EHRA 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Catheter Ablation
  • Session type : Poster Session
  • FP Number : P312

Authors : F Zoppo (Mirano,IT), S Indiani (Milano,IT), E Merola (Milano,IT), G Favaro (Milano,IT), A Lupo (Mirano,IT), F Zerbo (Mirano,IT), E Bacchiega (Mirano,IT), A Brazzolotto (Mirano,IT), V Bottazzo (Mirano,IT), L Lago (Mirano,IT)


F Zoppo1 , S Indiani2 , E Merola3 , G Favaro2 , A Lupo1 , F Zerbo1 , E Bacchiega1 , A Brazzolotto1 , V Bottazzo1 , L Lago1 , 1Dept of Cardiology - Mirano - Italy , 2St. Jude Medical - Milano - Italy , 3Biosense Webster - Milano - Italy ,

Europace ( 2017 ) 19 ( Supplement 3 ), iii50


The use of electroanatomic mapping (EA) during ablation allows the exposure of both patients and EP staff to  fluoroscopy (FL) to be reduced. However, for some EP techniques, such as aortic retro-navigation or trans-septal catheterization (for left heart navigation) FL is often required. Atrio-ventricular nodal reentrant tachycardia (AVNRT) is one of the most frequent supraventricular tachycardia (SVT) in young people.
Our aims were to assess the  safety and efficacy of AVNRT ablation procedures in which the Carto3™ and EnSiteTMNavX™  EA systems were used and to identify some key measures to avoid any FL use during procedures.


From June 2015 to October 2016, 60 consecutive patients underwent  ablation for SVT in our EP lab. In these patients, 20 AVNRT procedures (19 patients; 1 redo) were performed and were included in the present study (8 males, mean age 47+/-13.3 years). In all patients, 2 diagnostic catheters and a standard 4mm non-irrigated ablation catheter were used.


All patients successfully underwent ablation (1 patient underwent a "redo" procedure after 7 months). The Carto3™ EA system was used in 10 cases and the EnSite™ NavX™ EA was used in the remaining 10 (the study was not designed to compare the EA systems). No major procedural complications occurred. In one patient a  1st degree AV block was recorded (followed up by means of implantable loop recorder: Reveal LINQ™ Medtronic). At 3-month follow-up examination, all patients were free from AVNRT (and symptoms).The mean procedure time was 111.2 min ± 127.8 min; the mean EP study time was 24 ± 17 min. The mean fast anatomical mapping (FAM) time was 13 ± 4.4 min. The mean radiofrequency delivery time was 116 ± 122.7 sec. The FL time was 0 (Dose area product = 0 cGy*cm2).
The following steps enabled the use of FL to be safely and effectively avoided:
careful femoral vein cannulation slightly above the great  saphenous/femoral vein junction (to allow  straight femoral-iliac vein navigation);  "His-based" FAM reconstruction; the mandatory use of the His mapping catheter to match the real time catheter position with the His EA tag and the display and measurement of Kock triangle details.


AVNRT ablation may be safely and effectively performed by means of a real zero FL procedure, regardless of the EA system used. Some methodological steps may help to reach this target. These findings may be applicable to all right heart EP ablation procedures.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are